{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:14:58Z","timestamp":1790810098974,"version":"4.1.0"},"reference-count":25,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eagle Pharmaceuticals, Inc., Woodcliff Lake, NJ, USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Community-acquired bacterial pneumonia (CABP) is a common and costly cause of hospitalization. Although severe CABP (sCABP) occurs in 10\u201325% of all pneumonia hospitalizations, little generalizable data examine its characteristics and outcomes or hospital resource utilization. Methods: We conducted a retrospective single-group cohort study of adults within the IQVIA hospital Charge Data Master, 2018\u20132022. We identified CABP via an ICD-10 code algorithm and sCABP was defined as an episode requiring ICU care. We examined baseline characteristics and outcomes, including mortality, costs, and readmission rates. We developed models to identify risk factors associated with readmissions. Results: Among 24,149 patients with sCABP, 14,266 (58.4%) were \u226565 years old and 55.2% were male. The majority were hospitalized in large (300+ beds, 50.9%), urban (91.9%) teaching (62.7%) institutions in the US Southern region (52.3%). The mean (SD) Charlson Comorbidity Index was 1.35 (2.33). The most common comorbidities were hypertension (16.7%), diabetes mellitus (15.7%), and chronic obstructive pulmonary disease (COPD) (12.9%). Hospital mortality was 15.9%. The mean (SD) hospital length of stay (LOS) and costs were 13.6 (12.1) and USD 91,965 (USD 133,734), respectively. An amount of 20% required a readmission within 30 days. Readmission was most strongly associated with older age and the presence of select comorbidities (diabetes mellitus, congestive heart failure, and COPD), each with an odds ratio &gt; 1.4 and 95% confidence intervals excluding 1.0. Conclusions: Patients with sCABP comprise a large population with high mortality and 30-day readmissions. The intrinsic factors related to the latter lend themselves to early recognition and aggressive efforts at reducing complications.<\/jats:p>","DOI":"10.3390\/antibiotics14070642","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T03:53:02Z","timestamp":1750823582000},"page":"642","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Burden of Hospitalization and Rehospitalization Among Patients Hospitalized with Severe Community-Acquired Bacterial Pneumonia in the United States, 2018\u20132022"],"prefix":"10.3390","volume":"14","author":[{"given":"Marya D.","family":"Zilberberg","sequence":"first","affiliation":[{"name":"EviMed Research Group, LLC, Goshen, MA 01032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Eagle Pharmaceuticals, Inc., Woodcliff Lake, NJ 07677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6098-8013","authenticated-orcid":false,"given":"Valentin","family":"Curt","sequence":"additional","affiliation":[{"name":"Eagle Pharmaceuticals, Inc., Woodcliff Lake, NJ 07677, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-8328","authenticated-orcid":false,"given":"Andrew F.","family":"Shorr","sequence":"additional","affiliation":[{"name":"Washington Hospital Center, Washington, DC 20010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMra1312885","article-title":"Community-acquired pneumonia","volume":"371","author":"Musher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.vaccine.2015.05.001","article-title":"Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis","volume":"33","author":"Rozenbaum","year":"2015","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: Incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.chest.2017.09.041","article-title":"Burden of pneumonia-associated hospitalizations: United States, 2001\u20132014","volume":"153","author":"Hayes","year":"2018","journal-title":"Chest"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jinf.2016.04.008","article-title":"Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia","volume":"73","author":"Chalmers","year":"2016","journal-title":"J. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1017\/ice.2022.60","article-title":"Association of fluoroquinolones or cephalosporin plus macrolide with Clostridioides difficile infection (CDI) after treatment for community-acquired pneumonia","volume":"44","author":"Patel","year":"2023","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_8","unstructured":"Hospital-Acquired Condition Reduction Program (2025, April 15). Centers for Medicare and Medicaid Services, Available online: https:\/\/www.cms.gov\/medicare\/quality\/value-based-programs\/hospital-acquired-conditions."},{"key":"ref_9","unstructured":"Weiss, A.J., and Jiang, H.J. (2025, April 15). Overview of Clinical Conditions with Frequent and Costly Hospital Readmissions by Payer, 2018. July 2021. Agency for Healthcare Research and Quality, Available online: https:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb278-Conditions-Frequent-Readmissions-By-Payer-2018.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106476","DOI":"10.1016\/j.rmed.2021.106476","article-title":"Mortality and readmission in the year following hospitalization for pneumonia among US adults","volume":"185","author":"Averin","year":"2021","journal-title":"Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2214586","DOI":"10.1001\/jamanetworkopen.2022.14586","article-title":"Analysis of hospital-level readmission rates and variation in adverse events among patients with pneumonia in the United States","volume":"5","author":"Wang","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_12","unstructured":"(2025, April 15). Patient Protection and Affordable Care Act, HR 3590, 111th Congress (2010). PUB L No. 111\u2013148, Available online: https:\/\/www.congress.gov\/111\/plaws\/publ148\/PLAW-111publ148.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMsa1513024","article-title":"Readmissions, observation, and the hospital readmissions reduction program","volume":"374","author":"Zuckerman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.7326\/M16-0185","article-title":"Readmission rates after passage of the Hospital Readmissions Reduction Program: A pre-post analysis","volume":"166","author":"Wasfy","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/CIRCULATIONAHA.114.010270","article-title":"Hospital readmissions reduction program","volume":"131","author":"McIlvennan","year":"2015","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.chest.2020.03.051","article-title":"The burden of community-acquired pneumonia requiring admission to ICU in the United States","volume":"158","author":"Cavallazzi","year":"2020","journal-title":"Chest"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/CCM.0000000000005498","article-title":"Etiology, treatments, and outcomes of patients with severe community-acquired pneumonia in a large U.S. sample","volume":"50","author":"Haessler","year":"2022","journal-title":"Crit. Care Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.chest.2022.01.053","article-title":"Influenza testing and treatment among patients hospitalized with community-acquired pneumonia","volume":"162","author":"Deshpande","year":"2022","journal-title":"Chest"},{"key":"ref_19","unstructured":"Lopez, E., Neuman, T., Jacobson, G., and Levitt, L. (2025, April 15). How Much More Than Medicare Do Private Insurers Pay? A Review of the Literature. Kaiser Family Foundation, 15 April 2020. Available online: https:\/\/www.kff.org\/medicare\/issue-brief\/how-much-more-than-medicare-do-private-insurers-pay-a-review-of-the-literature\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/ash.2022.369","article-title":"A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections","volume":"3","author":"Malone","year":"2023","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","unstructured":"Human Subject Regulations Decision Charts (2025, April 15). US Department of Health and Human Services Office for Human Research Protections, Available online: https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/decision-charts\/index.html."},{"key":"ref_23","unstructured":"(2025, April 15). Available IQVIA Data. IQVIA. Available online: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/available-iqvia-data."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_25","unstructured":"(2025, April 15). Cost-to-Charge (CCR) Files. Agency for Healthcare Research and Quality, Available online: https:\/\/hcup-us.ahrq.gov\/db\/ccr\/costtocharge.jsp."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/7\/642\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:58:08Z","timestamp":1760032688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/7\/642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["antibiotics14070642"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14070642","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}